儿童先天性巨细胞病毒相关感音神经性听力损失的识别:基于普遍新生儿听力筛查、抗病毒治疗效果及长期听力结局
该研究基于美国明尼苏达大学狮子诊所儿科患者数据库(N=445)的回顾性病历回顾,识别出44例先天性巨细胞病毒(cCMV)患儿。其中33例(75%)存在不同程度和发病年龄的感音神经性听力损失(SNHL),17例(39%)双耳通过普遍新生儿听力筛查(UNHS),但其中6例(35%)最终出现双侧或单侧SNHL,平均诊断年龄20个月(中位12个月)。33例cCMV伴SNHL患儿中18例(55%)接受抗病毒药物(更昔洛韦和/或缬更昔洛韦)治疗,治疗组整体听力变化较未治疗组小(基线校正后预期平均差异-10.5 dB;95%CI -28.1至7.2 dB)。
要点
- cCMV患儿中39%双耳通过UNHS,但其中35%最终出现迟发性SNHL。
- 单侧未通过UNHS的cCMV患儿中50%对侧耳出现迟发性听力损失。
- 接受抗病毒治疗的cCMV伴SNHL患儿听力变化较未治疗组小(平均差异-10.5 dB)。
核心结论
- 本研究中双耳通过UNHS的cCMV患儿有35%出现迟发性SNHL,单侧未通过UNHS的患儿有50%对侧耳 later 出现SNHL,提示需长期听力学监测并可能考虑抗病毒治疗。
研究设计与样本
- 基于美国明尼苏达大学狮子诊所儿科患者数据库(N=445)的回顾性病历回顾,识别出44例cCMV患儿,回顾UNHS结果、SNHL临床病程及抗病毒治疗使用情况。
主要发现
- 44例cCMV患儿中33例(75%)存在不同程度和发病年龄的SNHL。
- 17例(39%)双耳通过UNHS,其中6例(35%)最终出现双侧或单侧SNHL,平均诊断年龄20个月(中位12个月)。
- 10例单侧未通过UNHS的患儿中5例(50%)对侧耳出现迟发性听力损失,平均诊断年龄24个月(中位4个月)。
- 11例(25%)双耳通过UNHS且最近一次随访(平均年龄19个月,SD 18个月)双耳听力正常。
- 33例cCMV伴SNHL患儿中18例(55%)接受抗病毒药物(更昔洛韦和/或缬更昔洛韦)治疗;治疗组与未治疗组听力均随时间进展,但治疗组整体听力变化较小(基线校正后预期平均差异-10.5 dB;95%CI -28.1至7.2 dB)。
临床怎么用
- 作者认为,这些发现对cCMV患儿的听力学监测和潜在抗病毒治疗具有意义;随着普遍cCMV筛查的推进,随访的关键方面将是适当的长期听力学监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Congenital cytomegalovirus (cCMV) is the most common cause of nongenetic sensorineural hearing loss (SNHL) in children. We examined the longitudinal hearing outcomes of children with cCMV in relation to their newborn hearing screening findings, and their use of antiviral therapy. DESIGN: The study was based on a retrospective chart review using a database of pediatric patients (N = 445) seen at the University of Minnesota Lions clinic. Chart review identified infants with cCMV, and records were reviewed for information about universal newborn hearing screen (UNHS) results, the clinical course of SNHL, and the use of antiviral therapy. RESULTS: A total of 44 children were identified with cCMV. In this group, 33 (75%) had SNHL of varying degree and age at onset. Notably, 17 (39%) children passed UNHS bilaterally. Of those children, 6 (35%) ultimately acquired bilateral or unilateral SNHL, detected at a mean age of 20 months (median age, 12 months). Five out of 10 children (50%) that did not pass UNHS in one ear acquired late-onset hearing loss in the contralateral ear, identified at a mean age of 24 months (median age, 4 months). Eleven (25%) children passed UNHS bilaterally and continued to demonstrate normal hearing in both ears at their most recent follow-up visit at a mean age of 19 months (SD, 18 months). Of the 33 children with cCMV and SNHL, 18 (55%) received antiviral medication (ganciclovir and/or valganciclovir). While, on average, both treated and untreated ears experienced a progression of hearing loss over time, the group that received antiviral treatment experienced less overall hearing change compared with the untreated group (baseline-adjusted expected mean difference, -10.5 dB; 95% confidence interval, -28.1 to 7.2 dB). CONCLUSIONS: Among children with cCMV included in this study who passed UNHS in both ears, 35% demonstrated delayed-onset SNHL. Notably, of those children who referred unilaterally, 50% later demonstrated SNHL in the contralateral ear. These findings have implications for audiological monitoring, and potentially antiviral therapy, of children with cCMV. As implementation of universal cCMV screening moves forward, a key aspect of follow-up will be appropriate long-term audiologic monitoring.
引用
- Rohren L, Shanley R, Smith M, et al. Congenital Cytomegalovirus-Associated Sensorineural Hearing Loss in Children: Identification Following Universal Newborn Hearing Screening, Effect of Antiviral Treatment, and Long-Term Hearing Outcomes. Ear Hear. 2023. PMID: 37563758. doi:10.1097/AUD.0000000000001411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。